Anebulo Pharmaceuticals
Austin
About Anebulo Pharmaceuticals
Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well-tolerated, and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $25.4M
- Funding stage: IPO
- Last round: Grant (Sep 2025)
- Ticker: nasdaq:ANEB
- Website: anebulo.com
- Phone: 512-598-0931
Industries & Categories
Biotechnology, Life Science, mHealth
Social Profiles
Canonical: https://fsome.com/organization/anebulo-pharmaceuticals-106486 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.